San Carlos, Calif., July 23, 2026
BeOne Medicines announced a $300 million expansion of its flagship Princeton West Innovation Campus in Hopewell, New Jersey, increasing the company’s total U.S. manufacturing investment to more than $1 billion. The expansion will significantly strengthen domestic production capabilities by adding small molecule drug manufacturing to the site’s existing biologics operations while supporting the continued development of the company’s growing oncology pipeline of more than 35 clinical and commercial-stage assets. The investment is expected to create approximately 120 new full-time jobs, reinforcing BeOne’s long-term commitment to expanding U.S. manufacturing capacity and accelerating the delivery of innovative cancer medicines to patients. Company leadership stated that the expansion also supports a stronger and more resilient pharmaceutical supply chain while positioning the facility for future growth.
New Manufacturing Facility Expands Production Capacity
The expansion includes construction of a new three-story, 145,000-square-foot manufacturing building adjacent to the company’s existing Hopewell facilities, increasing the total campus footprint to approximately 545,000 square feet. Once completed, the Princeton West Innovation Campus will operate as a fully integrated multi-platform manufacturing site, combining biologics manufacturing, small molecule drug production, drug packaging operations, quality control laboratories, and expanded office facilities within a single location. The new capacity is designed to support BeOne’s expanding hematology portfolio and broader oncology pipeline while providing additional manufacturing flexibility for future strategic collaborations and product development. The company expects the expanded facility to become fully operational in 2029, with total employment at the Hopewell campus increasing to approximately 240 employees.
Investment Supports Growing Global Oncology Pipeline
BeOne stated that the manufacturing expansion is designed to support its rapidly growing portfolio of innovative cancer therapies spanning blood cancers, breast cancer, gynecologic cancers, lung cancer, liver cancer, gastrointestinal cancers, and other solid tumors. The company’s research pipeline includes multiple therapeutic approaches such as small molecules, biologics, multispecific antibodies, targeted protein degraders, and antibody-drug conjugates (ADCs). By increasing manufacturing capacity within the United States, BeOne aims to strengthen its global development superhighway, an integrated platform combining clinical development, regulatory expertise, research, and manufacturing capabilities that enables faster and more cost-efficient development of oncology medicines. According to the company, nearly 6,000 employees worldwide are involved in clinical development and manufacturing activities supporting this integrated approach to cancer drug development.
Advertisement
Expansion Reinforces Long-Term U.S. Growth Strategy
The Princeton West Innovation Campus, originally opened in July 2024 following an $800 million investment, now exceeds $1 billion in total investment after the latest expansion. Situated on a 42-acre campus with more than one million square feet of future development capacity, the site serves as BeOne Medicines’ flagship U.S. manufacturing and clinical research hub. Across the United States, the company employs more than 2,000 people, generated nearly $2 billion in direct U.S. economic impact during 2025, and invested approximately $1 billion in research and development. BeOne is currently conducting 93 clinical trials across 45 states and one U.S. territory involving approximately 1,100 clinical trial sites and more than 650 investigators. With this latest manufacturing investment, BeOne Medicines continues expanding its U.S. footprint while strengthening production capabilities to support the global delivery of innovative oncology therapies to millions of cancer patients.
Source: BeOne Medicines press release
